{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-055809","form_type":"8-K/A","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2024-06-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.529609+00:00","generated_at":"2026-06-01T02:06:32.810869+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ABVC BioPharma amends licensing deal to allow $3.5M milestone paid incrementally","bullets":["On June 23, 2024, ABVC and BioLite amended licensing agreements with AiBtl BioPharma for CNS drugs MDD and ADHD.","The $3.5M second milestone payment can now be paid in increments (e.g., $50,000) at any time instead of lump sum.","Amendments apply to both the ABVC and BioLite license agreements; no other terms were changed.","Change suggests potential liquidity strain at licensee AiBtl BioPharma."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-055809","json":"https://secwatch.observer/filing/0001213900-24-055809.json","markdown":"https://secwatch.observer/filing/0001213900-24-055809.md","text":"https://secwatch.observer/filing/0001213900-24-055809.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024055809/0001213900-24-055809-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024055809/ea0208453-8ka1_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:06:32.810869+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}